Mitochondrial research to reduce diabetes-related heart failure 2 February 2024 Monash Institute of Pharmaceutical Sciences researcher Dr Miles De Blasio is undertaking research into heart failure experienced by people living with diabetes. “Diabetes-related heart failure is the major cause of morbidity and mortality in people living with diabetes,” Dr De Blasio said. “With more than 1.5 million Australians living with diabetes, and high rates of cardiac complications, improved prevention or treatment of those diabetes-related complications is urgently needed.” Dr De Blasio has received a 2024 Diabetes Australia Research Program (DARP) grant to explore cardiac mitochondrial dysfunction in the setting of diabetes. Mitochondria are membrane-bound cell organelles that power the cell’s biochemical reactions. These mitochondria become dysfunctional in the hearts of some people living with diabetes. Dr De Blasio will utilise mitochondria-targeted drugs (SS31, SkQ1, AP39) that bring about pre-clinical improvements in diabetic retinopathy, nephropathy, and other pathologies. These medications will now be investigated to explore if they can limit cardiac complications associated with diabetes. Diabetes Australia Group CEO Justine Cain said the successful DARP recipients were undertaking work that would change the lives of people with diabetes. “Research is critical in our fight to drive change to prevent, treat and, ultimately, cure diabetes,” Ms Cain said. “Diabetes research creates hope for the future.” Diabetes Australia has been funding diabetes research for more than 30 years through DARP grants. “Over the past 10 years alone, Diabetes Australia has invested more than $30 million in supporting nearly 500 critical research initiatives across all types of diabetes,” Ms Cain said. Diabetes Australia has launched a new campaign calling for more research funding called ‘Diabetes Research Changes Lives’. Members of the community can also support diabetes research by making a donation. Find out more about how to support us. About the Diabetes Australia Research Program: Established 37 years ago, the Diabetes Australia Research Program supports and develops outstanding diabetes research in Australia. The program funds research projects focused on the prevention, management, and cure of all types of diabetes, as well as fostering upcoming researchers. The program relies on the generosity and support of member organisations, corporates, and individual donors.
News 20 July 2026 Response to media reports from 60 Minutes, The Sydney Morning Herald, and The Age regarding regulation of diabetes technologies The safety of people living with diabetes must always come first. For many Australians, technologies such as insulin pumps and continuous glucose monitors are essential tools that help prevent dangerous high and low blood glucose levels, reduce the daily burden of living with diabetes and improve long-term health outcomes. For some individuals they can be life-changing or even life-saving. Continue Reading
Media releases 8 July 2026 Territory-led digital health innovation receives boost from national partnership A major funding boost will expand digital health solutions for complex care in the Northern Territory (NT), thanks to a joint investment from Diabetes Australia and Lilly Australia, in partnership with Menzies School of Health Research (Menzies). Continue Reading
Blog 8 July 2026 Taking the community’s voice to a global stage: IDF Western Pacific Region Congress 2026 This National Diabetes Week, we’re looking ahead to a landmark moment for our community, one that will see the voices,... Continue Reading